Last updated: October 12, 2023

Summarytoggle arrow icon

Transplantation is the process of transferring an organ or part of an organ (known as a graft) from one donor to either themselves (autologous transplantation) or another recipient (allogeneic transplantation) or their genetically identical recipient (isograft transplantation). In addition to being subject to strict legal requirements, the donor and recipient must be histocompatible in allogeneic transplantations to minimize the risk of transplant rejection. Because the major histocompatibility complex (MHC) is only perfectly matched in isotransplantation (involving the transfer of genetically identical tissue, e.g., between identical twins), allogeneic transplantation subsequently requires immunosuppressive therapy. Close follow-up and infection prevention measures (e.g., vaccination) are required because of the risks of posttransplant infection and graft rejection

Transplantation biologytoggle arrow icon

Transplant immunology

Major histocompatibility complex (MHC) and human leukocyte antigen (HLA)

See “Major histocompatibility complex” for more details.


Prerequisites for organ matching

Crossmatching (transplantation)

ABO compatibility

Rh compatibility is not required for solid organ transplantation. Both Rh compatibility and ABO compatibility are not essential for hematopoietic stem cell transplantation.


  • Principle
  • Coding of mismatch degree (HLA-DR, HLA-A, and HLA-B)
    • 0: no mismatch
    • 1: mismatch on either the paternal or maternal chromosome
    • 2: mismatch on both the paternal and maternal chromosome
    • 000: a complete match
    • 222: a complete mismatch
  • Odds of histocompatibility
    • For a sibling, the probability that the patient has an HLA compatible sibling is 1 - (0.75)n (where n is the number of siblings).
    • Between two randomly chosen, nonrelated individuals: 1 in 10,000
Types of graft based on histocompatibility between donor and recipient
Type Definition Examples
  • Graft originates from the recipient.
  • Graft originates from a genetically identical person (identical twin).
  • Graft originates from a genetically different person.
  • Graft originates from a different species (e.g., pig).

Immunosuppressive therapy is not required for autograft transplantation.

Overview of pretransplant and posttransplant measurestoggle arrow icon

Pretransplant evaluation [1][2]

Pretransplant infectious workup

Posttransplant infectious workup [3]

Because the symptoms of CMV infections can appear similar to those of transplant rejection, differentiating between conditions can be difficult.

Posttransplant immunosuppressive therapy [4]

Post solid organ transplant

Post allogeneic stem cell transplant

See “Prevention” in “Graft-versus-host disease.”

Immunosuppressive therapy is a balancing act: Too much immunosuppression, and the risk of infection increases; too little, and the risk of rejection increases.

Solid organ transplantationtoggle arrow icon

General principles [2]

  • Long-term management includes monitoring of:
  • Transplant centers typically guide posttransplant management for 3–12 months.
  • Consider a broad differential diagnosis and consult specialists for patients with complications (e.g., graft rejection, posttransplant infections).

Living donors

  • Overview
    • Nonvital organs and tissues (e.g., kidney or bone marrow) can be acquired from living donors.
    • The organ is retrieved from a living donor (usually a relative with a compatible blood type) at the time of the transplant surgery.
    • When there is no relative with blood type compatibility, a donor may engage in a swap transplantation with a nonrelated donor.
    • Prior to donation, donors must give full informed consent.
    • Donors may select the recipient of their donation.
    • Donors may not be paid for their donation, but can be reimbursed for associated costs (e.g., travel, food, lost wages).
    • Donor is usually healthy, which reduces the risk of complications for both donor and recipient.
    • Preoperative and perioperative immunomodulation is possible in the recipient.
    • Short cold ischemia time
    • Minimal waiting time
  • Disadvantages: increased risk of morbidity and mortality in the donor

Deceased and dying donors

Organ donation can save lives, and doctors play an important role in the organ donation system. Doctors should always honor their patients' end-of-life wishes and provide the best possible care, but they should also recognize the medical and social benefits of organ donation. When treating a dying patient, it is therefore important to initiate conversations with the patient and their family about the potential for organ donation. Due to the ethical concerns associated with organ donation, there are several procedures in place to protect the interests of the patient while expanding the practice of donation.

Legal and organizational aspects

  • An individual may register to become an organ donor (e.g., in a state donor registry) and can revoke this decision at any time.
  • Donors may specify the solid organs they wish to donate (e.g., heart, two lungs, two kidneys, pancreas, liver).
  • The organ is retrieved from a donor after brain-death (DBD) or a donor after circulatory death (DCD).
  • Deceased patients who have not specifically declined to become donors (e.g., in an advance directive) may be considered if consent is obtained from the next of kin.
  • Dying patients (e.g, terminally ill, in palliative care) who have not previously opted-in to the donation system may also be considered for organ donation.
  • To avoid any conflict of interest, the decision to end life-sustaining care is always made by a medical team that is independent of the transplant team.
  • If the individual is a donor candidate and did not explicitly decline to donate organs (e.g., in a living will) the hospital notifies the local Organ Procurement Organization (OPO).
  • Factors that the OPO will consider:
    • Is there an organ donation plan?
    • If no such plan exists, did the deceased declare their intention to donate organs (e.g., by registering in the state organ donor registry)?
    • If the patient did not declare their intention to donate organs, the OPO discusses the possibility of donation with the patient's next of kin.
    • Is the patient a suitable candidate for donation?

Organ assessment and matching

  • The Organ Procurement and Transplant Network (OPTN) is a national system that links all professionals involved in organ donation and transplantation (e.g., OPOs, transplant centers, histocompatibility laboratories).
  • It is administered by the United Network for Organ Sharing (UNOS), a private nonprofit organization contracted by the federal government.
  • The UNOS manages the national transplant waiting list and works with OPOs to match donors with recipients.
  • Guidelines for matching include donor compatibility, medical utility, geography, and survival benefit of the transplant.
  • The following are the expected waiting periods for new transplant candidates:
  • Contraindications for the acceptance of organs include: [5][6]
  • Circumstances under which organ transplants can be accepted include:

Organ preservation

  • Hypothermic solutions
    • Extracellular solutions (e.g., Bretschneider solution): ↑ Na+, ↓ K+
    • Intracellular solutions (e.g., University of Wisconsin solution, St. Thomas cardioplegia solution): ↓ Na+, ↑ K+
  • Ischemic times
    • Warm ischemia time: time from the withdrawal of life support in the donor to the initiation of cold organ preservation
    • Cold ischemia time: time from the initiation of cold organ preservation to the warming of the organ within the recipient following the restoration of blood perfusion

A prolonged ischemic time increases the risk of organ dysfunction in the posttransplant period.

Transplantation sites

Overview of organ transplantation sites
Description Examples
  • The graft is placed in the normal anatomical position.
  • The diseased or nonfunctional organ being replaced is removed.
  • The graft is placed in a site other than the normal anatomical position.
  • The nonfunctional organ is usually left in place.

Renal transplantationtoggle arrow icon


Two healthy, fully functioning kidneys are an essential requirement for kidney donation by a living donor.

The left kidney is preferred for living-donor transplantation as it has a longer renal vein.

Complications of renal transplantation [9][10]

The most important complications are listed. Timelines are estimates.

Any time post-transplant

Acute postoperative (< 1 week)

Early (1–12 weeks)

Late (> 12 weeks)

Posttransplant care [15]

Diagnostic algorithm for renal dysfunction following renal transplantation

  1. Consider prerenal causes of acute renal failure.
  2. Measure urine protein and order a dipstick urine test for hematuria.


The graft functions stays functional for ∼ 14 years, longer if received from a living donor.

Overview of survival rates after kidney transplantation
1-year survival rate 2-year survival rate 5-year survival rate
Cadaveric graft 88% 81% 71%
Graft from living donor 94% 93% 84%

Renal transplantation has a better prognosis than dialysis in end-stage renal disease.

Liver transplantationtoggle arrow icon

Overview [17]

Complications of liver transplantation [18][19][20]

The most important complications are listed. Timelines are estimates.

Vascular complications [21]

Biliary complications [22]

Other complications

Diagnostic algorithm in the case of clinical or laboratory features of hepatic dysfunction

Posttransplant care


Heart transplantationtoggle arrow icon

Overview [24][25][26]


Posttransplant care


Overview of survival rates after heart transplantation
1-year survival rate 3-year survival rate 5-year survival rate
Primary transplants
  • 87%
  • 79%
  • 72%
  • 82%
  • 67%
  • 58%

Lung transplantationtoggle arrow icon

Overview [27]

Complications of lung transplantation [29]

The most important complications are listed. Timelines are estimates.

Any time post-transplant

Graft rejection


Early (< 4 weeks)

Late (> 4 weeks) [33]

Signs of airway obstruction and post-obstructive pneumonia are common manifestations of late lung transplant complications.

Post-transplant care


  • Median survival for all adult recipients: 5.7 years
  • 1-year survival rate: 78%
  • 5-year survival rate: 51%

Hematopoietic stem cell transplantationtoggle arrow icon

Hematopoietic stem cell

Overview of hematopoietic stem cell grafts
Bone marrow transplant Peripheral blood stem cell transplant Umbilical cord blood transplant
Risk of graft-vs-host disease (GvHD)
  • Lowest
  • Highest
  • Low
  • By 3 weeks
  • By 2 weeks
  • By 4 weeks

Types of hematopoietic stem cell transplantation (HSCT)

Autologous vs. allogeneic stem cell transplantation
Autologous stem cell transplantation Allogeneic stem cell transplantation
Indications [34]
Preferred graft source


  1. Preparation of a hematopoietic stem cell graft from the donor using bone marrow aspirate, peripheral blood, or umbilical cord blood
  2. Transplant preparative regimen: recipient preparation using high-dose chemotherapy and/or total body irradiation
  3. Intravenous injection of the harvested hematopoietic stem cells
  4. Stem cell engraftment: anatomical and functional incorporation of transfused hematopoietic stem cells in the recipient's bone marrow
  5. In allogeneic stem cell transplantation: regimen to prevent GvHD


Hepatic venoocclusive disease (hepatic VOD) [35]

Engraftment syndrome [36]


The mortality rate of allogeneic stem cell transplantation is declining but is still as high as 50%.
When considering a regimen to prevent GvHD following allogeneic HSCT for hematological malignancies, the risk of GvHD should always be weighed against the loss of a beneficial graft-vs-tumor effect and the risk of graft failure due to drug toxicity.

Complicationstoggle arrow icon

Complications after transplantation can be divided into graft-related (graft rejection, graft-versus-host disease) and immunosuppression-related complications (infection, malignancy).

We list the most important complications. The selection is not exhaustive.

Graft rejectiontoggle arrow icon


  • Definition: graft failure resulting from damage by the recipient's immune response
Types of graft rejection
Hyperacute rejection Acute rejection Chronic rejection
  • < 48 hours after transplantation, usually within minutes to hours
  • < 6 months after transplantation, usually within weeks to months
  • > 6 months after transplantation, usually after a few years
Clinical features
  • Pain in the graft region
  • Graft edema
  • Fever and deterioration of general condition
  • Slow, progressive loss of organ function
  • Graft removal
  • Graft removal
  • N/A

Hyperacute rejection

Acute rejection

Chronic rejection

Graft rejection manifests with organ failure and is very difficult to distinguish from other posttransplant complications. A biopsy is required to confirm the diagnosis.

Graft-versus-host disease (GvHD)toggle arrow icon


Types of GvHD

Acute GvHD Chronic GvHD
Main affected organs
Treatment [41]

Acute GvHD

Chronic GvHD [40]

The skin, intestines, and liver are the most commonly affected organs in GvHD.

Immunosuppression-related complicationstoggle arrow icon


Overview of posttransplant infections
Time of onset Infection

Early onset

(< 1 month after transplantation)

Late onset 1–6 months
6–12 months
> 12 months

Posttransplant malignancy

Referencestoggle arrow icon

  1. Valenzuela NM, Reed EF. Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol. 2013; 1034: p.41-70.doi: 10.1007/978-1-62703-493-7_2 . | Open in Read by QxMD
  2. Corrêa RRM, Machado JR, da Silva MV, et al. The Importance of C4d in Biopsies of Kidney Transplant Recipients. Clinical and Developmental Immunology. 2013; 2013: p.1-8.doi: 10.1155/2013/678180 . | Open in Read by QxMD
  3. Williams WW, Taheri D, Tolkoff-Rubin N, Colvin RB. Clinical role of the renal transplant biopsy. Nat Rev Nephrol. 2012; 8 (2): p.110-121.doi: 10.1038/nrneph.2011.213 . | Open in Read by QxMD
  4. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation. 2005; 11 (12): p.945-956.doi: 10.1016/j.bbmt.2005.09.004 . | Open in Read by QxMD
  5. Martin PJ, Rizzo JD, Wingard JR et al. First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012; 18 (8): p.1150-1163.doi: 10.1016/j.bbmt.2012.04.005 . | Open in Read by QxMD
  6. $The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update.
  7. Mancini D, Lietz K. Selection of Cardiac Transplantation Candidates in 2010. Circulation. 2010; 122: p.173-183.doi: 10.1161/CIRCULATIONAHA.109.858076 . | Open in Read by QxMD
  8. Canter CE, Shaddy RE, Bernstein D et al. Indications for heart transplantation in pediatric heart disease. Circulation. 2007; 115 (5): p.658-676.doi: 10.1161/CIRCULATIONAHA.106.180449 . | Open in Read by QxMD
  9. Fischer SA, Avery RK. Screening of Donor and Recipient Prior to Solid Organ Transplantation. Am J Transplant. 2009; 9: p.S7-S18.doi: 10.1111/j.1600-6143.2009.02888.x . | Open in Read by QxMD
  10. American Society of Transplantation. Primer on Transplantation. John Wiley & Sons ; 2010
  11. Enderby C, Keller CA. An overview of immunosuppression in solid organ transplantation. Am J Manag Care. 2015; 21 (1 Suppl): p.s12-23.
  12. Weill D et al.. A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. The Journal of Heart and Lung Transplantation. 2015; 34 (1): p.1-15.doi: 10.1016/j.healun.2014.06.014 . | Open in Read by QxMD
  13. Organ Procurement and Transplantation Network - National Data. Updated: August 21, 2019. Accessed: August 23, 2019.
  14. Garrido G, Dhillon GS. Medical Course and Complications After Lung Transplantation. Springer International Publishing ; 2018: p. 279-288
  15. Martinu T, Chen DF, Palmer SM. Acute Rejection and Humoral Sensitization in Lung Transplant Recipients. Proc Am Thorac Soc. 2009; 6 (1): p.54-65.doi: 10.1513/pats.200808-080go . | Open in Read by QxMD
  16. Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment―A consensus report from the Pulmonary Council of the ISHLT. The Journal of Heart and Lung Transplantation. 2019; 38 (5): p.493-503.doi: 10.1016/j.healun.2019.03.009 . | Open in Read by QxMD
  17. Porteous MK, Diamond JM, Christie JD. Primary graft dysfunction. Curr Opin Organ Transplant. 2015; 20 (5): p.506-514.doi: 10.1097/mot.0000000000000232 . | Open in Read by QxMD
  18. Santacruz JF, Mehta AC. Airway Complications and Management after Lung Transplantation: Ischemia, Dehiscence, and Stenosis. Proc Am Thorac Soc. 2009; 6 (1): p.79-93.doi: 10.1513/pats.200808-094go . | Open in Read by QxMD
  19. Kotloff RM, Blosser S, Fulda GJ, et al. Management of the Potential Organ Donor in the ICU. Crit Care Med. 2015; 43 (6): p.1291-1325.doi: 10.1097/ccm.0000000000000958 . | Open in Read by QxMD
  20. New Organ Procurement Organization (OPO) Survey Protocol and Guidance Revisions in Appendix Y of the State Operations Manual (SOM). Updated: August 10, 2018. Accessed: October 16, 2020.
  21. Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV. Updated: November 20, 2015. Accessed: August 26, 2019.
  22. Nashar K, Sureshkumar KK. Update on kidney transplantation in human immunodeficiency virus infected recipients. World J Nephrol. 2016; 5 (4): p.300.doi: 10.5527/wjn.v5.i4.300 . | Open in Read by QxMD
  23. Weber TM, Lockhart ME. Renal transplant complications. Abdom Imaging. 2013; 38 (5): p.1144-1154.doi: 10.1007/s00261-013-0005-9 . | Open in Read by QxMD
  24. Cassini MF , de Andrade MF, Junior ST. Surgical Complications of Renal Transplantation. Understanding the Complexities of Kidney Transplantation. 2011.doi: 10.5772/16767 . | Open in Read by QxMD
  25. Menn-Josephy H, Beck Jr. LH. Recurrent glomerular disease in the kidney allograft. Front. Biosci. 2015; 7 (1): p.155-170.doi: 10.2741/e723 . | Open in Read by QxMD
  26. Shafiq A C, Ajay S, Ahmed H. Urine Leak Following Kidney Transplantation: An Evidence-based Management Plan. J Clini Nephrol. 2018; 2 (3): p.044-052.doi: 10.29328/journal.jcn.1001018 . | Open in Read by QxMD
  27. Chen W, Kayler LK, Zand MS, Muttana R, Chernyak V, DeBoccardo GO. Transplant renal artery stenosis: clinical manifestations, diagnosis and therapy. Clin Kidney J. 2014; 8 (1): p.71-78.doi: 10.1093/ckj/sfu132 . | Open in Read by QxMD
  28. Sarier M, Yayar O, Yavuz A, Turgut H, Kukul E. Update on the Management of Urological Problems Following Kidney Transplantation. Urol Int. 2021; 105 (7-8): p.541-547.doi: 10.1159/000512885 . | Open in Read by QxMD
  29. Josephson MA. Monitoring and Managing Graft Health in the Kidney Transplant Recipient. Clin J Am Soc Nephrol. 2011; 6 (7): p.1774-1780.doi: 10.2215/cjn.01230211 . | Open in Read by QxMD
  30. Mannon RB. Delayed Graft Function: The AKI of Kidney Transplantation. Nephron. 2018; 140 (2): p.94-98.doi: 10.1159/000491558 . | Open in Read by QxMD
  31. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Updated: March 1, 2014. Accessed: March 27, 2017.
  32. Moreno R, Berenguer M. Post-liver transplantation medical complications. Ann Hepatol. 2006; 5 (2): p.77-85.doi: 10.1016/s1665-2681(19)32022-8 . | Open in Read by QxMD
  33. Craig EV, Heller MT. Complications of liver transplant. Abdom Radiol. 2019; 46 (1): p.43-67.doi: 10.1007/s00261-019-02340-5 . | Open in Read by QxMD
  34. Porrett PM, Hsu J, Shaked A. Late surgical complications following liver transplantation. Liver Transpl. 2009; 15 (S2): p.S12-S18.doi: 10.1002/lt.21893 . | Open in Read by QxMD
  35. Piardi T, Lhuaire M, Bruno O, et al.. Vascular complications following liver transplantation: A literature review of advances in 2015. World J Hepatol. 2016; 8 (1): p.36.doi: 10.4254/wjh.v8.i1.36 . | Open in Read by QxMD
  36. Moy BT, Birk JW. A Review on the Management of Biliary Complications after Orthotopic Liver Transplantation. J Clin Transl Hepatol. 2019; 7 (1): p.1-11.doi: 10.14218/jcth.2018.00028 . | Open in Read by QxMD
  37. Choudhary NS, Saigal S, Bansal RK, Saraf N, Gautam D, Soin AS. Acute and Chronic Rejection After Liver Transplantation: What A Clinician Needs to Know. Journal of Clinical and Experimental Hepatology. 2017; 7 (4): p.358-366.doi: 10.1016/j.jceh.2017.10.003 . | Open in Read by QxMD
  38. Majhail NS, Farnia SH, Carpenter PA et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015; 21 (11): p.1863-1869.doi: 10.1016/j.bbmt.2015.07.032 . | Open in Read by QxMD
  39. Senzolo M. Veno occlusive disease: Update on clinical management. World Journal of Gastroenterology. 2007; 13 (29): p.3918.doi: 10.3748/wjg.v13.i29.3918 . | Open in Read by QxMD
  40. KA AA, E M. Engraftment Syndrome: An Updated Review. Journal of Stem Cell Biology and Transplantation. 2017; 01 (03).doi: 10.21767/2575-7725.100016 . | Open in Read by QxMD
  41. Gutiérrez-García G, Rovira M, Magnano L, et al. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018; 53 (12): p.1541-1547.doi: 10.1038/s41409-018-0189-2 . | Open in Read by QxMD
  42. Kasper DL, Fauci AS, Hauser SL, Longo DL, Lameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. McGraw-Hill Education ; 2015
  43. Brunicardi F, Andersen D, Billiar T, et al.. Schwartz's Principles of Surgery. McGraw-Hill Education ; 2014
  44. Williams NS, Bulstrode C, O'Connell PR. Bailey & Love's Short Practice of Surgery. CRC Press ; 2013

Icon of a lock3 free articles remaining

You have 3 free member-only articles left this month. Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer